GSK shelves cough drug acquired in $2B deal
完全音声プレビュー
0:00
0:00
#1
British pharmaceutical giant GSK announced on Friday that it would discontinue development of camlipixant, an experimental chronic cough treatment it acquired through a two-billion-dollar deal three years ago.
英國製藥巨頭葛蘭素史克於週五宣布，將停止研發 camlipixant，這是一款該公司於三年前透過一筆二十億美元的交易中所收購的實驗性慢性咳嗽治療藥物。
#2
The drug discontinuation followed mixed Phase 3 data, with the company conceding that the medication had failed to meet nearly all primary endpoints in two late-stage clinical trials.
在第三期臨床試驗數據呈現好壞參半的結果後，該藥物隨即宣告終止研發，該公司也承認這款藥物在兩項晚期臨床試驗中，幾乎未能達到所有的主要療效指標。
#3
GSK emphasized that the limited efficacy demonstrated was unlikely to transform patient care in any meaningful way.
葛蘭素史克強調，所顯示出的有限療效不太可能以任何有意義的方式改變患者護理。
#4
GSK had originally gained access to camlipixant upon acquiring Bellus Health, a move that came despite the drug having initially failed in a Phase 2 trial.
葛蘭素史克最初是在收購 Bellus Health 時獲得 camlipixant 的使用權，儘管該藥物最初在第二期臨床試驗中失敗，但仍進行了這項收購行動。
#5
A subsequent mid-stage study had delivered more promising results, showing a statistically significant reduction in cough frequency.
隨後進行的一項中階段研究取得了更具前景的結果，顯示出在咳嗽頻率上具有統計學意義的顯著降低。
#6
The lower dose of fifty milligrams taken twice daily, which had proved effective in that earlier study, was the highest dose evaluated in the Phase 3 clinical trials.
在先前的研究中被證實有效的每日兩次、每次五十毫克的較低劑量，是第三期臨床試驗中所評估的最高劑量。
#7
The termination effectively closes what had been a blockbuster opportunity for GSK, which had hoped to incorporate camlipixant into its existing portfolio of respiratory drugs, including asthma and chronic obstructive pulmonary disease treatments such as Trelegy and Anoro.
這項終止實際上關閉了葛蘭素史克原本視為暢銷藥物的絕佳機會，該公司曾希望將 camlipixant 納入其現有的呼吸道藥物產品組合中，其中包括氣喘以及慢性阻塞性肺病治療藥物，例如 Trelegy 和 Anoro。
#8
Nevertheless, the company confirmed that it is continuing Phase 2 trials of camlipixant in patients with irritable bowel syndrome, suggesting the drug may yet find a viable therapeutic application.
然而，該公司證實，目前正持續進行 camlipixant 在大腸激躁症患者身上的第二期臨床試驗，這表明該藥物仍有可能找到可行的治療應用。
#9
Camlipixant is now the third drug in the P2X3 antagonist class to fail in pharma development, following similar setbacks encountered by Bayer and Merck and Company.
camlipixant 目前已成為 P2X3 拮抗劑類別中第三款在製藥研發中宣告失敗的藥物，此前拜耳和默沙東也遭遇過類似的挫折。
#10
Merck had reportedly spent more than five hundred million dollars to gain control of its own candidate in this class.
據報導，默沙東已花費超過五億美元，以取得其在該類別中自身候選藥物的控制權。
#11
Industry analysts have cautioned that these repeated failures raise fundamental questions about whether P2X3 antagonists can deliver sufficient clinical benefit for chronic cough patients.
行業分析師警告，這些接連的失敗對 P2X3 拮抗劑是否能為慢性咳嗽患者提供足夠的臨床療效提出了根本性的質疑。
#12
The setback does, however, clear away a competitive threat to Trevi Therapeutics, which is advancing a fundamentally different type of treatment for chronic cough.
然而，這次挫折確實為 Trevi Therapeutics 掃除了一個競爭威脅，該公司目前正在開發一種本質上完全不同的慢性咳嗽治療方法。
#13
Had camlipixant succeeded, it would have posed a significant challenge to Trevi's market prospects.
若 camlipixant 取得成功，它本會對 Trevi 的市場前景構成重大挑戰。
#14
Investors will undoubtedly be scrutinizing GSK's broader pipeline strategy in the coming weeks, particularly given the substantial financial commitment the company made to secure this now-abandoned asset.
投資人無疑將在未來幾週內仔細審視葛蘭素史克的更廣泛產品線策略，特別是考慮到該公司為了獲取這個如今已被放棄的資產而做出的重大財務承諾。